Boehringer Ingelheim licenses multiple Dark Antigens from Enara Bio to develop immunotherapies for NSCLC
Dark Antigens are a rich source of novel cancer-specific targets derived from regions of the genome historically thought to be non-coding, known as the genomic dark matter